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1 Welcome to the inaugural issue 
of Advance, a biannual research 
digest for alumni, friends and 
colleagues.  
  Advance is produced by the 
University of Tennessee Graduate 
School of Medicine to highlight 
the wide-ranging research and 
people who are part of the 
research enterprise of the region’s 
only academic medical center: the 
University of Tennessee Medical 
Center and UT Graduate School 
of Medicine.
 We are grateful to the leaders of 
University of Tennessee Medical Center for their support of this 
communication and for their unflagging support of the spirit of 
inquiry that pervades our institutions.  In addition to excellence in 
patient care and education, our academic medical center sponsors 
extensive research in both the clinical and laboratory settings.  In 
that endeavor, we collaborate with the University of Tennessee, 
Knoxville (UTK), UT College of Veterinary Medicine, Oak Ridge 
National Laboratory (ORNL) and other research institutions to 
seek answers to complex medical problems.  We train students, 
physicians and scientists to become the researchers of the future 
and approach health care with the curiosity that will lead to 
improvement in the lives of our patients.
 Research and researchers, alike, take many forms. Some of 
our researchers have taken clinical problems to the laboratory and 
are delving into very fundamental questions on the molecular 
level. Some are clinicians performing prospective trials of new 
techniques or treatments. Others are trying to find ways to 
improve the delivery of healthcare by looking retrospectively in 
order to parse out clues to enhance future outcomes. 
 In partnership with our colleagues at UTK, we are looking 
at medical care delivery and how decisions are made, hoping 
to enhance patient safety and access as well as reduce the cost 
of medical care. With ORNL, we are looking at how images 
are interpreted with an eye to eventual computerization. The 
UTK College of Engineering is helping develop new devices and 
educational simulators for our physicians and scientists, so they 
may effectively practice in our new Medical Simulation Center, 
improving their skills in a virtual setting. 
 Our researchers are scientists dedicated to pure science, and 
they are physicians who in addition to providing clinical care seek 
answers through research that will also help their patients. It is 
the nature of an academic medical center like ours to pursue new 
solutions and solve diverse questions in the quest for excellence.
 All of this intellectual vigor requires hefty funding and support 
from the institutions.  The immediate return is not always visible.  
The UT Graduate School of Medicine supports the ongoing 
research efforts because we understand that the atmosphere of 
inquiry is vital to our mission of superior patient care  
and education. 
 Our academic medical center sustains this effort through 
its budget, grants from funding agencies and foundations and 
through generous gifts from benefactors who understand the 
crucial role medical research plays for our community and for 
mankind. In addition, some departments and physicians allocate 
portions of their practice income to research in areas of their 
expertise. 
 The results, as you will see in this publication, create a robust 
catalogue of outstanding work portending an exciting future for 
the University of Tennessee Medical Center and the patients  
we serve.
Mitchell Goldman, M.D.
Assistant Dean for Research
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Alan Solomon, M.D.
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 Stone by stone, this laborer crafts walls and 
pathways across his tranquil property.  The 
stonework, an avocation, is precise and lovely 
and reflects the man’s drive and vision, traits that 
define Alan Solomon, M.D., and his work at 
the UT Graduate School of Medicine, where he 
serves as professor of Medicine and directs the 
Human Immunology and Cancer Program.  He 
has given most of his adult years as a physician 
and medical researcher to improve the quality of 
life of his patients.  
North and South
 A native New Yorker, Solomon graduated 
from Duke University School of Medicine in 
1957 and then completed an internship at 
Mount Sinai Hospital in New York.  He then did 
something most medical school graduates did not 
do:  He chose to undergo another three years of 
clinical training at Montefiore and Mount Sinai 
hospitals, plus four years of research training 
at the National Institutes of Health’s National 
Cancer Institute and The Rockefeller Institute for 
Medical Research.
 Finally, he finished his self-imposed rigors of 
training and began working. Then the phone rang.
Tennessee Calling
 “I got a call from Dr. Amoz Chernoff, who 
was director of the UT Memorial Research 
Center,” Solomon says.  “He asked if I would be 
interested in coming to Tennessee.”
 The year was 1966. Medical research had few 
regulations, and without the internet, researchers 
waited months for new information to reach 
library shelves. MRI, CT and PET scans did not 
exist, and anti-cancer drugs were only a dream.
 In this setting, Solomon came to UT where 
his research and clinic duties were devoted 
to cancer.  In 1992, he was one of eight 
medical scientists in the U.S. to be named an 
American Cancer Society Clinical Research 
3Professor.   Subsequently, his efforts have focused 
on a disease known as amyloidosis.  
 Amyloid is the term for a misfolded, “gum-up-
the-works” form of a variety of proteins that can 
form hair-like fibers, or fibrils, that are deposited 
into vital organs, like the heart, kidneys, pancreas 
or brain.  This process leads to organ failure and 
eventually, death.  Amyloid-associated illnesses 
include Alzheimer’s disease, adult (Type-2) 
diabetes, rheumatoid arthritis and a condition 
related to multiple myeloma called primary or 
AL amyloidosis.  
 “The goal of our amyloid research is to 
develop new means of diagnosis and more 
effective treatment,” Solomon says.  “We are 
convinced that we can make a significant impact 
on these diseases by improving the prognoses and 
reducing the suffering of our patients.”  
 Today, the fruits of this research are being 
applied directly to the patient.
 “To see the discoveries in the laboratory 
being translated to the clinic indeed is a major 
achievement, but even though 
these illnesses cannot be cured 
at present, we will at least make 
them more chronic and improve 
the quality of life.”
Promise, Faith, Family
 “Everyone, regardless of who 
they are, can do something to 
contribute to the healing of the 
world,” Solomon says, reflecting 
belief in a central Jewish tenant 
and a strong paternal influence. 
 Solomon’s father came from a 
very poor immigrant family and 
dropped out of school at age 
12 to support his family.  He 
found a way to go to school at 
night and eventually completed 
law school to become a senior 
partner in a large law firm 
in New York.  He was the recipient of several 
honorary doctoral degrees and four endowed 
professorships in law and medicine.  
 Today, rooted in faith and family, backed by a 
lifetime of wisdom and spurred by a passionate 
quest, Solomon made a promise almost  
15 years ago.
 “A patient of mine had amyloid disease 
and later died.  At her funeral, I promised her 
husband that we’d do something to affect this 
disease that took his wife, and when I make a 
promise, I try to keep it,” he says.
 “I owe a debt of gratitude to my patients and 
my talented colleagues who truly have been 
partners in this work.  I’m also thankful to the 
private and public agencies that have provided 
the financial support to fund our research.”
 Just as one stone leads to the next, Solomon 
remains optimistic that through his and his 
colleagues’ research, advances in medicine will 
lead to others to benefit all humanity.
Why this matters:
Early detection of melanoma and other skin cancers 
can save a life.
Jim Lewis, M.D., in his “sun suit.”
 You might have seen him in his “sun 
suit.”  Sans jacket and tie, it’s a giant, friendly 
sunshine.  But the sun suit doesn’t just attract 
attention.  For Jim Lewis, M.D., assistant 
professor of Surgery and surgical oncologist, 
it’s a silly way to reach people about a 
serious subject.
 Skin cancers are, 
indeed, serious, even 
deadly, but they are 
often preventable.  More 
than 120,000 people are 
diagnosed each year with 
melanoma, which is cancer 
of the pigment cells and the 
deadliest form of skin cancer.  
Of those, about 45% are invasive, 
resulting in someone dying from 
melanoma every hour in the 
U.S.  Melanoma, if caught 
early, can be cured  
through surgery.
 Other skin cancers also should not be 
ignored: squamous cell carcinoma, cancer 
of the outer layer of skin cells; and basal cell 
carcinoma, cancer of the deepest layer of skin 
cells and the most common skin cancer.
 To help people understand the importance 
of caring for their skin and identifying 
abnormal skin lesions, Lewis, along with 
Valerie Sams, M.D., third-year resident in 
Surgery, and Georgette Samaras, UT Cancer 
Institute’s outreach coordinator, have embarked 
on a community outreach program, 
Taking It to the Streets:  Research That’s More than Skin Deep
SunScreeners
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Jim Lewis, M.D., in his “sun suit.”
called SunScreeners.  The program provides on-
site skin screenings and allows community 
members to enroll in a research program that 
provides evaluation and diagnosis of skin lesions 
and support for further examination by  
a specialist.
 “We believe we must educate people about 
skin cancers,” Lewis said.  “Early detection 
leads to cures, so we take the opportunity for 
screenings to the communities.”
 Donning his sun suit, Lewis and his team set 
up SunScreeners at outdoor sports events and 
community festivals and visit senior centers and 
wellness programs at area businesses.  
 Some community members just want to have 
a skin blemish examined on the spot, but others 
sign up for the research program, which includes 
on-site dermal photography of the skin lesion.
 “Using the dermal photography, we classify 
lesions from benign [not harmful] to very 
problematic,” Lewis said.  “We will then contact 
participants with results of their screenings and 
for some, help them find a dermatologist or other 
specialist.  Six months later, we will follow up 
with the participants to evaluate the effectiveness 
of the program.
 “We’ve screened more than one thousand 
people, and the majority had only benign lesions. 
For the small percent of people who were referred 
to a specialist, we believe we potentially saved 
their lives,” he concluded.
 For more information about SunScreeners or 
how you can participate in the research program, 
contact Georgette Samaras at 865-305-8577.
5
Advice from the 
SunScreeners
Prevent Sunburn
Limit or avoid sun exposure between  
10 a.m. and 4 p.m.
Avoid Tanning Beds
Tanning bed users have 2.5 times the 
risk of squamous cell carcinoma and 1.5 
times the risk for basal cell carcinoma.  
Exposure to tanning beds before age 35 
increases melanoma risk by 75%.
Use Sunscreen
“SPF” refers to “sun protection 
factor,” the amount of time you will 
be protected from a burn.  Use a 
sunscreen with an SPF of 15 or higher.  
Sunscreens should be liberally applied 
about 20 minutes before sun exposure.
Melanoma: 
What To Look For
Melanoma, the deadliest form of  
skin cancer, can be identified in  
several ways:
• A spot that is new, irregularly shaped 
and dark brownish with darker or 
black areas
• A mole that grows darker, bigger or 
firmer, itches or tingles and/or flakes 
and bleeds
• A lesion with an irregular border
• A bump that is shiny, firm and  
dome shaped
• A dark lesion under a fingernail or 
toenail or on the palm or sole.
If you are concerned about your skin, 
call your doctor today.
Tom Terrell, M.D., and colleagues are investigating  
a connection between genetics and concussion.
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 Could your child be genetically predisposed 
to a more severe concussion?  Could his genetics 
indicate a slower recovery from a concussion?  
Tom Terrell, M.D, associate professor in 
Family Medicine and associate director of the 
Sports Medicine Fellowship, and Ken Bielak, 
M.D., associate professor and Sports Medicine 
Fellowship director, are leading a study to answer 
those questions.  
 Terrell and Bielak are attempting to find a 
biological link to the association between genetic 
makeup and concussion risk in athletes.  The 
study is funded by the National Operating 
Committee on Standards for Athletic Equipment 
and is the largest prospective cohort study of its 
kind in the U.S.  It has the participation of 15 
colleges and universities in the Southeast and 
about 2,500 athletes in collision sports.  
 Concussion is an injury to the brain due to 
rapid rotation of the head caused by trauma to the 
head or other part of the body.  It causes transient 
alteration in the brain’s neurological status and can 
have long-term effects.  Loss of consciousness does 
not necessarily accompany concussion.
 In the study, athletes who sustain a concussion 
voluntarily submit DNA samples, which are 
analyzed at Duke University.  The team is 
investigating whether genetic polymorphisms 
(variations in individual DNA sequence between 
individuals) increase the risk of sustaining 
concussion; influence the severity of acute sports 
concussions; and impact the duration  
of symptoms.
 So far, 120 concussions have been collected, 
and results of the genetic analysis are forthcoming. 
  
Genetics and Concussion
Why this matters:
Athletes suffer more than one million concussions 
each year.  As more light is shed on the serious 
nature of brain injury, including concussion, we 
learn more about how to care for our athletes 
and accident victims.  
7“We believe the study will reveal if there is genetic 
predisposition to more severe concussions,” Terrell 
said.  “These findings may potentially determine 
how quickly athletes should return to play or 
whether they should play collision sports at all.  
For those who have suffered concussions, our 
findings might provide promising information 
about the risk for additional concussions and the 
duration of recovery time.  With larger long-
term studies, we may be able to predict who is 
vulnerable to more severe concussions.”
 This milestone in the research marks not an 
ending but a springboard for further study.  Terrell 
and Bielak now are working with researchers in 
the Molecular Imaging and Translational Research 
Program as well as physicians in the Emergency 
Department.  The goal of this collaboration is 
to ultimately help accident victims who suffer 
brain injury and investigate new ways to image 
concussion using positron emission tomography/
computed tomography (PET/CT).  
 For more information about the concussion 
study or to register to participate in the study, visit 
www.concussionresearch.com or contact Terrell at 
865-305-9352. 
Concussion Center
The Department of Family Medicine 
is establishing a Concussion 
Center in its new Sports Medicine 
Clinic to serve concussed athletes 
in the community.  The Sports 
Medicine Clinic offers services from 
sports medicine physicians for a 
variety of sports- and non-sports-
related accidents and injuries. For 
information call 865-305-9352.
Why this matters:
Clinical trials advance healthcare and bring 
treatments more quickly to patients. 
Deborah Tuggle is participating in a clinical trial under the 
direction of William Smith, M.D., and believes it’s her way to 
help future generations.
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 Clinical trials are a type of medical research 
conducted to collect data on the safety and 
effectiveness of new treatments, most commonly 
devices, vaccines or drugs.
 Product development exists in four phases:
 Phase I - Short trials evaluating basic safety  
 and metabolism
 Phase II - Early evaluation of effectiveness,  
 safety and appropriate dose
 Phase III - Large trials to determine efficacy  
 and side effects for submission to the FDA  
 for approval 
 Phase IV - Post-marketing studies to answer  
 additional questions about marketed drugs or  
 determine new indications. 
 “This is my way of contributing to future 
generations,” says Deborah Tuggle, a clinical 
trials participant.  “Medicines that have helped 
me in the past were developed through studies 
just like these, and eventually these will help 
someone.  I like being a part of that process.”
 
 Individuals who participate in clinical trials 
may benefit in a variety of ways:
• Playing a more active role in their own  
health care
• Being involved in the discovery of new 
treatments for those suffering from  
various illnesses 
• Gaining access to new research treatments 
before they are widely available
• Undergoing medical examinations and lab 
work at no cost and
• Possibly being compensated for their travel, 
time and inconvenience.
 “Clinical trials research offers an opportunity 
for patients to be a part of the future of 
medicine,” says Timothy Panella, M.D., chair 
of Department of Medicine. “If people do not 
participate in these studies, the advancement of 
medical care comes to a standstill.  We stand on 
the shoulders of others, and the patients at the 
top edge are those participating in clinical trials; 
it’s altruism at its finest.”
 Volunteer Research Group (VRG) is an entity 
for pharmaceutical-sponsored clinical trials 
located at the University of Tennessee Medical 
Center.  VRG currently is seeking volunteers 
with high cholesterol, low kidney function, 
liver disease, congestive heart failure or prior 
myocardial infarction and for adults who are 
generally healthy.  For a complete list of enrolling 
studies and to find out how you can become a 
participant, visit www.VRGUT.com or  
call 865-305-DRUG (3784).
The ABCs of Clinical 
Trials and How You 
Can Benefit
William B. Smith, M.D., President, Volunteer Research Group
UT Graduate School of Medicine  
surgical residents and faculty 
physicians operate.
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 Why do some residents in the rigorous surgical 
residency program succeed…and some do not?  
Daniel Alterman, M.D., sixth-year resident in 
General Surgery led a study to find out.  
 “Other studies have shown that gender, 
marital status and ethnicity make a difference in 
the success rate of surgical residents,” Alterman 
said.  “Our study found these factors make little 
difference.”
 Alterman says the study showed predictors of 
good clinical and academic performance during   
surgical residency are top scores on Step 1 of the 
U.S. Medical Licensing Exam (USMLE), a good 
interview impression and accomplishments in high 
performance areas outside of medicine, such as 
Division I college athletics and the performing arts.
    These results add to the growing body of 
literature that highlights the importance of the 
USMLE Step 1 score as a key component in 
resident screening and selection.
     Next issue: Watch for resident research in 
other departments.
Recipe for Success: 
Surgery Residents
Why this matters:
Now, the UT Graduate School of Medicine has 
objective markers to help focus the screening 
process for surgical residents, which will result 
in more successful surgeons for the community.
In BRIef »»»»»»
Eric R. Carlson,  
D.M.D, M.D.
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 It’s a subject many people are too embarrassed 
to discuss.  Not so with Eric R. Carlson, D.M.D., 
M.D., chair of Oral and Maxillofacial Surgery.  
His research is showing findings so startling that 
he believes he must talk about it:  The possible 
association between oral cancer and intimate oral 
contact.
 For the first decade of Carlson’s practice 
beginning in 1990, oral cancer in the patients 
he treated was primarily caused by well accepted 
carcinogens, namely tobacco and alcohol.  The 
patients were typically older men.  
  Starting in 2000, Carlson began seeing young, 
non-tobacco-using, otherwise healthy men 
presenting with oral cancer, most commonly 
tongue cancer.  He believed the cancer might be 
caused by human papillomavirus (HPV), a DNA 
virus known to cause cervical cancer in women.
 Carlson was right.  
  After studying the patients’ tumors, he found 
HPV in more than half of the specimens, and 
more research has led to the belief that HPV is 
likely transmitted through intimate oral contact.
  In cervical cancer, the incorporation of HPV in 
a woman’s DNA can, under certain circumstances, 
produce cancer proteins (oncoproteins) that 
inhibit two important tumor suppressor genes.  
Carlson believes this is the same process that can 
cause cancer in the mouths and throats of people, 
particularly those with more frequent exposure.  
It is becoming well 
accepted that more 
frequent exposure to 
the virus increases the 
risk of developing an 
HPV-related  
oral cancer.
   Even more shocking, 
          the American Medical  
        Association recently    
stated that 50% of men are HPV positive and 
80% of women are HPV positive by the age of 50. 
  “Over the past decade, societal practices have 
changed,” Carlson said.  “HPV-related oral cancer 
is becoming more commonly observed, but we 
are narrowing the gap in our knowledge of these 
cancers.  Next, we want to determine why some 
men have HPV but do not develop oral cancer 
and study the cancer of monogamous partners to 
see if the HPV viruses match in men with HPV-
related oral cancers and their female partners with 
HPV-related disease in the cervix.  This scientific 
observation will get us closer to concluding a 
cause-and-effect relationship associated with this 
social disease.”
  In the meantime, counseling young people 
about the risks of exposure to HPV is imperative.  
Also, HPV vaccines for both young women  
and men between the ages of nine and 26  
are available.  
A New Disease on the Rise: 
HPV-Related Oral Cancer
In BRIef »»»»»»
Why this matters:
We now know there are different types of oral 
cancer:  Those associated with HPV and oral 
cancers not associated with HPV.  An important 
part of our observation is that patients with HPV-
related oral cancers have a better prognosis than 
those patients with oral cancers associated with 
the excessive use of tobacco and alcohol.  Also, 
revealing this social disease keeps our younger 
population healthier.  
Deidra Mountain, Ph.D., and  
her team are researching causes  
of vascular disease.
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 Estrogen and progesterone could be 
contributing to vascular disease, and the 
researchers in the Vascular Research Laboratory are 
asking, “Why?”  The team is using information 
discovered years ago by physicians in the Division 
of Vascular/Transplant Surgery that showed 
women receiving hormone replacement therapy 
(HRT) who also had vascular disease requiring 
interventions often had more adverse outcomes 
after their procedures than women who were 
not undergoing HRT.  The team is identifying 
the vascular cell mechanisms that seem to be 
influenced by the estrogen and progesterone in 
HRT with the goal of developing ways to  
help women.
 Now, the team, led by Deidra Mountain, 
Ph.D., assistant professor of Vascular/Transplant 
Surgery, are continuing their fight against vascular 
disease by examining gene therapy.  Gene therapy 
is the delivery of genetic material into a living cell 
that incorporates the new genetic instructions 
to alter a disease process.  This type of therapy 
shows promise in the treatment of many diseases, 
including vascular, but delivering the genes in 
a safe and non-toxic way has been a formidable 
problem.  
 Mountain’s team is testing a delivery agent 
made from biodegradable polymer that does 
not have the harmful side effects of traditional 
agents.  They have successfully silenced (altered) 
dysfunctional genes in laboratory tests and will 
proceed with testing in biological samples.  Success 
here could lead to gene therapy for vascular disease 
and research into many other diseases.
Identifying How HRT and 
Gene Therapy Affect Vascular Disease
Why this matters:
Instead of treating symptoms of vascular disease, 
gene therapy alters the function of genes that are 
contributing to the disease, therefore, helping the 
body heal itself or prevent the development of 
the disease.  Gene therapy could be an innovative 
treatment for many diseases.
In BRIef »»»»»»
ODAM protein (fluorescent green) is photographed among 
breast cancer cells (blue).  The ODAM protein could help in 
the diagnosis of breast and other cancers.
Why this matters:
While a relatively low number of people who suffer 
from certain dental tumors could benefit from 
the identification of this novel protein, thousands 
who suffer from breast, lung and other cancers 
will benefit from the new research and possible 
diagnostic treatment potentials that the studies 
on ODAM will have opened.
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 Daniel Kestler, Ph.D., Charles Bruker, M.D., 
and their colleagues in the Human Immunology 
and Cancer Program have investigated a 
protein, called ODAM (odontogenic ameloblast 
associated), in certain odontogenic (dental) tumors. 
Interestingly, it has been detected in breast, lung 
and gastrointestinal cancers, melanoma and other 
malignancies.  The findings and discoveries on 
this molecule could improve the diagnosis and 
treatment of some cancers, of particular interest to 
the team’s clinical members, surgical oncologists 
John Bell, M.D., and James Lewis, M.D.
 Proteins are the primary components of cells, 
affecting their growth, function and regulation.  
The researchers found that localization of the 
ODAM protein in cells correlated with the stage 
of breast cancer and melanoma, a cancer of skin’s 
pigment cells.  Further, the expression of the 
ODAM protein was introduced into cultures of 
highly invasive human breast tumor cells in the 
laboratory, and the researchers saw significant 
increase of tumor growth and invasiveness.   
 A number of patients who have participated 
in the study also were found to have measurable 
levels of antibodies to the protein in their blood.
 “This suggests an immune recognition of this 
protein as a possible tumor expressed antigen and 
that the molecule or its interactions may prove 
important for cancer evaluation and therapy,”  
said Kestler.  
 If the protein can serve as a tumor biomarker (a 
substance that can be traced in the body), cancers 
can be diagnosed earlier or perhaps linked to 
specific treatment, which might improve chances 
for survival.
 The protein, created by a natural gene 
previously not known to produce a protein, 
was first discovered in the Molecular Biology 
Laboratory by Alan Solomon, M.D., director, 
Human Immunology and Cancer Program.
Dental Protein Could Improve 
Breast Cancer Diagnosis
In BRIef »»»»»»
Residents and fellows at the UT Graduate School of Medicine 
review research presentations.
Your Chance to Advance
 The people at the UT Graduate School of Medicine would be happy 
to discuss our research programs and how your support can help advance 
healthcare.  For information about philanthropic giving to the UT 
Graduate School of Medicine Office of Research, please contact the 
development office at 865-305-6611 or development@utmck.edu. 
 If you would like more information about any of the research 
programs described in this issue of Advance, please contact the UT 
Graduate School of Medicine at 865-305-9290 or visit us online:  
http://gsm.utmck.edu/research/main.cfm.
                                              Thank you.
Residents, Fellows 
PResent ReseaRch
 More than 40 residents and fellows presented 
abstracts during Research Days that summarized 
research in both case studies and original 
projects.  Topics included blood transfusion 
in trauma; dental infection and correlation to 
systemic illness; improving resident-patient 
communication; MRSA infections in the head 
and neck; gene therapy and others.
 “Research Days are a direct extension of 
the Graduate School of Medicine’s mission 
to improve patient care through research and 
scholarly activity,” said William Metheny, 
assistant dean, Graduate Medical and Dental 
Education.  “The events are celebrations of the 
culmination of faculty mentoring that teaches 
the next generation the discipline of scientific 
inquiry and discovery.”
nih GRant awaRded FoR  
wound healinG ReseaRch
A research study jointly led by the UT Graduate 
School of Medicine Shock, Trauma and 
Nutrition laboratory and Advanced Plasma 
Products Inc. received funding from the National 
Institutes of Health.  The Small Business 
Innovation Research grant, totaling $341,000, 
will fund research in the development of an 
atmospheric plasma application to improve 
wound healing.  
ReseaRcheR RecoGnized  
at conFeRence
Christopher Stephens, Ph.D., assistant professor, 
Regenerative Medicine laboratory, received 
an Award of Excellence at the Comparative 
and Experimental Medicine and Public 
Health Symposium held at the University of 
Tennessee College of Veterinary Medicine.  The 
award recognized his research described in a 
presentation, “Generation of Three-Dimensional 
Tissue Using Stem Cell Seeding of Polymeric 
Scaffolds.”
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